Your browser is no longer supported. Please, upgrade your browser.
CNST Constellation Pharmaceuticals, Inc. daily Stock Chart
Constellation Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.95 Insider Own0.30% Shs Outstand25.24M Perf Week8.92%
Market Cap372.79M Forward P/E- EPS next Y-3.12 Insider Trans- Shs Float24.89M Perf Month82.35%
Income-76.10M PEG- EPS next Q-0.83 Inst Own81.80% Short Float2.49% Perf Quarter77.95%
Sales- P/S- EPS this Y-16.80% Inst Trans0.21% Short Ratio5.08 Perf Half Y18.16%
Book/sh2.60 P/B5.68 EPS next Y-1.00% ROA-61.90% Target Price17.29 Perf Year137.08%
Cash/sh3.89 P/C3.80 EPS next 5Y- ROE-80.10% 52W Range4.01 - 15.63 Perf YTD268.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High182.66% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low1003.12% ATR1.22
Employees82 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)96.57 Volatility7.78% 11.32%
OptionableNo Debt/Eq0.00 EPS Q/Q-82.20% Profit Margin- Rel Volume123.50 Prev Close14.77
ShortableYes LT Debt/Eq0.29 EarningsNov 14 BMO Payout- Avg Volume122.15K Price44.18
Recom1.60 SMA20248.90% SMA50363.36% SMA200342.31% Volume2,554,859 Change199.12%
Sep-04-19Initiated RBC Capital Mkts Outperform $20
Jan-29-19Initiated Robert W. Baird Outperform $17
Dec-20-18Initiated H.C. Wainwright Buy $18
Dec-20-18Initiated H.C. Wainwright Buy
Aug-13-18Initiated JP Morgan Overweight $17
Nov-06-19 09:00AM  Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results GlobeNewswire +199.12%
Oct-31-19 10:00AM  Here's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST) Zacks
Oct-14-19 08:06AM  Will Constellation Pharmaceuticals Continue to Surge Higher? Zacks +9.99%
Oct-10-19 07:00AM  Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH GlobeNewswire
Oct-04-19 08:52AM  Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-01-19 07:00AM  Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors GlobeNewswire +17.49%
Sep-26-19 12:00PM  Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-24-19 07:00AM  Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise GlobeNewswire
Sep-23-19 07:17PM  Investors May Want to Follow the Progress of These Biotechs -5.91%
Aug-21-19 09:00AM  Constellation Pharmaceuticals to Participate in Two Investor Conferences GlobeNewswire
Aug-07-19 04:05PM  Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results GlobeNewswire
Jul-25-19 01:39PM  Did You Manage To Avoid Constellation Pharmaceuticals's (NASDAQ:CNST) 16% Share Price Drop? Simply Wall St.
Jun-13-19 02:57PM  Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-12-19 09:00AM  Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209 GlobeNewswire -5.80%
Jun-03-19 09:00AM  Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients GlobeNewswire +7.19%
May-31-19 11:00AM  Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference GlobeNewswire
May-23-19 10:28AM  Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial GlobeNewswire
May-20-19 07:00AM  Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting GlobeNewswire -15.15%
May-16-19 09:00AM  Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts GlobeNewswire
May-08-19 04:15PM  Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results GlobeNewswire
Apr-19-19 08:00AM  Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day GlobeNewswire
Apr-10-19 07:01PM  Jim Cramer: What Dirty Lemon Tells Us About Market Tops and Millennials
Mar-14-19 05:24PM  Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire +9.65%
Mar-06-19 02:35PM  Constellation Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -8.06%
Mar-04-19 07:00AM  Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer GlobeNewswire
Feb-25-19 09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks +13.14%
Feb-22-19 01:24PM  Constellation Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -9.51%
Feb-20-19 07:00AM  Constellation Pharmaceuticals Announces Appointment to Board of Directors GlobeNewswire
Feb-12-19 08:52AM  Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates Zacks
Feb-08-19 10:05AM  Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y Zacks
10:03AM  MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y Zacks
Feb-05-19 09:17AM  Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings? Zacks +6.83%
Feb-04-19 09:50AM  Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings? Zacks +15.83%
Jan-03-19 07:00AM  Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs GlobeNewswire +5.02%
Dec-20-18 01:34PM  Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire -5.31%
Dec-11-18 08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 04:49PM  Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) GlobeNewswire
Nov-29-18 02:00PM  Constellation Pharmaceuticals to Present at BMO Healthcare Conference GlobeNewswire
09:22AM  Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer GlobeNewswire
Nov-21-18 07:20AM  Factors of Influence in 2018, Key Indicators and Opportunity within Sphere 3D, Solar Senior Capital, The Intergroup, Constellation Pharmaceuticals, Sonoma Pharmaceuticals, and OFS Capital New Research Emphasizes Economic Growth GlobeNewswire
Nov-15-18 07:00AM  Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference GlobeNewswire
Nov-08-18 04:30PM  Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results GlobeNewswire
Nov-02-18 01:08PM  Constellation Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire +5.41%
Nov-01-18 07:00AM  Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis GlobeNewswire
Oct-10-18 04:30PM  Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis GlobeNewswire
Sep-28-18 02:48PM  4 IPOs That Went Public in Q3 Including Tilray InvestorPlace
Sep-12-18 09:00AM  Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker Award GlobeNewswire
Sep-04-18 06:30AM  Constellation Pharmaceuticals Announces Appointments to Board of Directors GlobeNewswire -13.06%
Aug-14-18 04:15PM  Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results GlobeNewswire +11.11%
Aug-13-18 11:58AM  BMO, Oppenheimer Out Bullish On Constellation Pharma's Cancer Treatment Opportunity Benzinga
Jul-19-18 11:47AM  Constellation Pharmaceuticals shares slide 25% in trading debut MarketWatch
11:31AM  [$$] Health-Care Companies Keep Up Rapid Pace of IPOs The Wall Street Journal
07:56AM  Constellation Pharmaceuticals IPO prices at midpoint, but shares offered cut by 25% MarketWatch
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.